Balaji Amines Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 24 May 2026 | Chemicals & Petrochemicals | Market Cap: ₹6.9K Cr
The company targets around 25% to 30% volume growth by end of FY27 compared to current levels. Management expects 20% to 30% volume growth in the coming financial year (FY27), driven by new plants such as Dimethyl Ether (DME), Acetonitrile, and N-Methyl Morpholine (NMM), as well as increased demand from battery industries.
From Balaji Amines Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,078
Market Cap
₹6.9K Cr
P/E Ratio
33.9
Revenue Rank
Margin Rank
How does Balaji Amines Ltd rank in Chemicals & Petrochemicals?
Compare Balaji Amines Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Balaji Amines Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹395 Cr, net profit ₹65 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →The company targets around 25% to 30% volume growth by end of FY27 compared to current levels.
- →For the current year, a conservative volume growth of 10% to 15% is expected.
- →Growth drivers include new products: Dimethyl Ether (DME), Acetonitrile (ACN), and N-Methyl Morpholine (NMM).
- →DME plant commissioning expected in Q1 FY27, with utilization likely at 30%-40% in the current year and up to 80%-90% in coming years.
- →Balaji Specialty Chemicals subsidiary is investing significantly, with INR 350-400 crores capex planned in phase 1, supporting expansion.
- →Revenue target of INR 3,000 crores by FY28, supported by expanded specialty product portfolio and DME.
- →EBITDA margins are expected to be sustainable between 22%-23% alongside volume growth.
- →Continuous ramp-up expected as battery industries and other end markets stabilize, supporting further volume increases.
📈 Profitability & Margins
Rank 3- →Management expects 20% to 30% volume growth in the coming financial year (FY27), driven by new plants such as Dimethyl Ether (DME), Acetonitrile, and N-Methyl Morpholine (NMM), as well as increased demand from battery industries.
- →EBITDA margins are anticipated to sustain at around 22% to 23%.
- →The company aims to increase utilization of the DME plant to 30%-40% in FY27, with further ramp-up to 50%-60% by year-end, reaching 80%-90% in subsequent years.
- →Consolidated EBITDA grew 11% in FY26, with EBITDA margin improving from 19% to 20%, and PAT margin improving from 11% to 12%.
- →EPS for Q4 FY26 stood at INR 19.99, showing improvements over previous quarters.
- →The company plans steady operational improvements and capacity expansions, expecting these to support revenue growth up to INR 2,000 crores by FY28.
- →They will continue prudent raw material management to maintain margins amid price volatility.
🏗️ Capital Expenditure Plans
Yes- →Standalone capex for FY27: Around INR 20 crores balance for 3 products (DME, NMM, ACN), mostly already paid for equipment.
- →Balaji Specialty Chemicals subsidiary: Total Phase 1 capex INR 750 crores; INR 350-400 crores planned. For FY27, >INR 100 crores already spent, plus another INR 200-250 crores expected.
- →Greenfield and brownfield expansions ongoing; Phase 1 for greenfield partially in production (ethylamine, DMC) with modifications underway for specialty chemicals plant.
- →Dimethyl Ether (DME) plant: Commissioning expected in Q1 FY27, pending road transportation permission; capacity ramp-up projected reaching 50-60% by FY27-end, 80-90% in subsequent years.
- →Capex combined on consolidated basis for FY27 estimated between INR 275-290 crores.
- →Management inviting investors soon to visit plants to witness ongoing expansions.
💰 Fundraising & Capital Structure
No information- →The company has not provided any definitive update on an IPO or stake increase; it's "too early" to discuss IPO plans.
- →Any decision on IPO or increasing stakes will depend on the market introduction of products and board approvals.
- →Current consolidated debt is INR133 crores, mainly due to ongoing expansion activities.
- →For ongoing expansions, the company has planned capex of around INR275 to INR290 crores for FY27, funded internally or through current financial position (no explicit mention of new fundraising).
- →No mention of any new equity or debt fundraising in the transcript; focus seems to be on completing expansions and utilizing existing capacities.
- →The management assures disciplined capital management and a strong balance sheet without indicating immediate plans for fresh fundraising.
📋 Order Book & Pipeline
No information- →The company is in the process of expanding its product range with new products such as Dimethyl Ether (DME), Acetonitrile, and N-Methylmorpholine (NMM).
- →For DME, the plant is commissioned but awaiting road transport permission; production is ongoing, and once permission is granted, utilization is expected to increase to 30-40% in the current year and up to 80-90% in later years.
- →Prospective customers for DME have been approached, and trial shipments with 500 kg cylinders are underway to secure bulk orders.
- →Some battery chemical products have received commercial orders, but full-scale demand depends on battery manufacturers ramping up operations.
- →The greenfield and brownfield capex projects (e.g., Balaji Specialty Chemicals) are ongoing, with modifications progressing and investor plant visits planned soon.
- →No specific numeric order book or pending orders disclosed, but the company indicated growing demand and upcoming volume growth of 20-30% driven by new products and markets.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Balaji Amines Ltd Q4 FY26 results?
The company targets around 25% to 30% volume growth by end of FY27 compared to current levels. Management expects 20% to 30% volume growth in the coming financial year (FY27), driven by new plants such as Dimethyl Ether (DME), Acetonitrile, and N-Methyl Morpholine (NMM), as well as increased demand from battery industries.
What is Balaji Amines Ltd share price analysis?
Balaji Amines Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 33.9 with a market cap of ₹6,914 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaji Amines Ltd planning capital expenditure?
Standalone capex for FY27: Around INR 20 crores balance for 3 products (DME, NMM, ACN), mostly already paid for equipment.
Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.